Inducible tissue constructs and uses thereof
US-2024287463-A1 · Aug 29, 2024 · US
Hepatocyte construct and method for producing the same
US2020291350A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2020291350-A1 |
| Application number | US-201916502232-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jul 3, 2019 |
| Priority date | Mar 12, 2019 |
| Publication date | Sep 17, 2020 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
A hepatocyte construct including an aggregate containing hepatocytes and adherent cells that are non-hepatocytes, and wherein the hepatocytes include ballooned hepatocytes is provided. Further, a method for producing a hepatocyte construct, comprising: (i) forming an aggregate by aggregating a cell group comprising hepatocytes and adherent cells that are non-hepatocytes; and (ii) culturing the aggregate is provided.
First claim
Opening claim text (preview).
1 . A hepatocyte construct comprising: an aggregate containing hepatocytes and adherent cells that are non-hepatocytes, wherein the hepatocytes include ballooned hepatocytes. 2 . The hepatocyte construct according to claim 1 , wherein the adherent cells are fibroblasts or mesenchymal stem cells. 3 . The hepatocyte construct according to claim 1 , wherein the adherent cells are primate fibroblasts. 4 . The hepatocyte construct according to claim 1 , wherein the aggregate is a cell sheet. 5 . The hepatocyte construct according to claim 1 , wherein sonic hedgehog (SHH) protein expression per cell is higher than that in normal hepatocytes. 6 . The hepatocyte construct according to claim 1 , wherein the hepatocytes contain a Mallory-Denk body. 7 . The hepatocyte construct according to claim 1 , wherein the hepatocytes are primary hepatocytes. 8 . The hepatocyte construct according to claim 1 , wherein the hepatocyte construct expresses α-SMA. 9 . The hepatocyte construct according to claim 1 , wherein the ratio of the hepatocytes to the adherent cells is from 10:1 to 1:10. 10 . A method for producing a hepatocyte construct comprising: (i) forming an aggregate by aggregating a cell group containing hepatocytes and adherent cells that are non-hepatocytes; and (ii) culturing the aggregate. 11 . The method according to claim 10 , wherein the adherent cells are fibroblasts or mesenchymal stem cells. 12 . The method according to claim 10 , wherein the adherent cells are primate fibroblasts. 13 . The method according to claim 10 , wherein the hepatocytes are primary hepatocytes. 14 . The method according to claim 10 , wherein the forming comprises: (i-1) seeding and culturing the hepatocytes on a first culture substrate; (i-2) seeding and culturing the adherent cells on the first culture substrate on which the hepatocytes are seeded; and (i-3) forming the aggregate by releasing the cell group containing the hepatocytes and the adherent cells from the first culture substrate. 15 . The method according to claim 10 , wherein the culturing is having the aggregate adhered onto a second culture substrate and culturing the aggregate. 16 . The method according to claim 10 , wherein in the forming, a ratio of the hepatocytes to the adherent cells is from 10:1 to 1:10. 17 . A hepatocyte construct which is produced by the method according to claim 10 .
Assignees
Inventors
Classifications
Steroid hormones · CPC title
Insulin-transferrin; Insulin-transferrin-selenium · CPC title
- C12N5/0671Primary
Three-dimensional culture, tissue culture or organ culture; Encapsulated cells · CPC title
Adult fibroblasts · CPC title
Collagen; Gelatin · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2020291350A1 cover?
- A hepatocyte construct including an aggregate containing hepatocytes and adherent cells that are non-hepatocytes, and wherein the hepatocytes include ballooned hepatocytes is provided. Further, a method for producing a hepatocyte construct, comprising: (i) forming an aggregate by aggregating a cell group comprising hepatocytes and adherent cells that are non-hepatocytes; and (ii) culturing the …
- Who is the assignee on this patent?
- Nihon Kohden Corp, Univ Tokyo Womens Medical
- What technology area does this patent fall under?
- Primary CPC classification C12N5/0671. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Sep 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).